在皮状细胞癌中探索新的治疗点
Madeline Rhind1, Khadijah Abdulhaleem2, Ryan Zhu3
1Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.
Gynecologic oncology
|November 23, 2025
概括
这项研究评估了在状平细胞癌 (VSCC) 中的抗体药物合物 (ADC) 标和免疫标记物. 人类乳头瘤病毒独立的VSCC显示免疫细胞透和PD-L1表达的增加,表明免疫治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药物开发 药物开发
背景情况:
- 状状细胞癌 (VSCC) 是一种罕见的癌症,具有有限的先进治疗选择.
- 抗体药物联合体 (ADCs) 提供了向治疗方法.
- 了解瘤免疫微环境对于开发免疫疗法至关重要.
研究的目的:
- 在VSCC.中识别潜在的抗体药物合物 (ADC) 标.
- 分析免疫微环境,包括免疫细胞透和PD-L1表达.
- 探索ADC目标,免疫标记物和人类乳头瘤病毒 (HPV) 状态之间的相关性.
主要方法:
- 免疫组织化学 (IHC) 用于评估108名VSCC患者样本中6个潜在的ADC标 (HER2,TROP2,TF,NECTIN4,FOLR1,CLDN18.2) 的表达.
- 使用H分数量化TROP2,TF和NECTIN4的表达水平.
- 计算了多重IHC评估的免疫标志物 (CD3 +,CD8 +,CD68 +,PD-1 / PD-L1) 和编程死亡连接物1 (PD-L1) 的综合阳性得分 (CPS).
主要成果:
- 在TROP2 (74%),TF (73%) 和NECTIN4 (53%) 中,表达度中等到高,表明潜在的ADC标.
- CLDN18.2和FOLR1是负的,HER2的表达是最小的.
- 所有病例都表现出PD-L1表达 (CPS ≥1),中位数CPS为66. 与HPV相关的瘤相比,HPV独立的瘤显示出更高的CD8+和CD68+细胞透率和更高的PD-L1 CPS中位数.
结论:
- 在VSCC中,TROP2,TF和NECTIN4是ADC的有希望的目标.
- 这项研究为在VSCC中结合ADC和免疫检查点抑制剂的临床试验提供了理由.
- 独立于HPV的VSCC瘤似乎在免疫学上更活跃,这表明免疫治疗可能有好处.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


